课题基金 / 基金详情

Identifying genetic factors that determine responsiveness to therapeutic HIF2a pathway inactivation in Birt-Hogg-Dubé syndrome-associated renal cell carcinoma

Identifying genetic factors that determine responsiveness to therapeutic HIF2a pathway inactivation in Birt-Hogg-Dubé syndrome-associated renal cell carcinoma
确定 Birt-Hogg-Dubé 综合征相关肾细胞癌中 HIF2a 通路失活治疗反应性的遗传因素
批准号：
473563
负责人：
Johnson Fraser
金额：
$10.93万
依托单位：
Amsterdam UMC - Academic Medical Center (Netherlands)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-10-01 至 2025-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=473563&lang=en
关键词：
Belzutifan Birt-Hogg-Dubé Syndrome Functional Genomics Hereditary Disease Hypoxia Inducible Factor Personalized Targeted Therapies Pooled Genome-Wide Lentiviral Crispr Screens Target Discovery

项目摘要

项目成果

Johnson Fraser的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Birt-Hogg-Dubé syndrome (BHD) is a predisposition to renal cell carcinoma (RCC) caused by inherited mutations of the Folliculin (FLCN) gene. The lifetime risk for BHD patients to develop RCC is approximately 20%. Timely diagnosis of BHD by DNA analysis he
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibiting lung cancer by targeting disulfide reductase enzymes with a novel small molecule that induces reactive oxygen species
A novel mechanism of reactive oxygen species-induced synthetic lethality in lung cancer
The maternal embryonic leucine zipper kinase as a therapeutic target in castration-resistant prostate cancer
  • 批准号：
    367163
  • 项目类别：
    Studentship Programs
  • 资助金额：
    $1.27万
  • 财政年份：
    2016
  • 负责人：
    Johnson Fraser
  • 依托单位：
    University of British Columbia